

Verastem, Inc.  
Form SC 13D/A  
February 08, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**SCHEDULE 13D/A**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

**Verastem, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.0001 per share**

(Title of Class of Securities)

**92337C104**

(CUSIP Number)

**Christoph Westphal, M.D., Ph.D.**

**Longwood Fund, L.P.**

**Prudential Tower, Suite 1555**

**800 Boylston Street**

**Boston, Massachusetts 02199**

**(617) 351-2590**

**with a copy to:**

**Sarah Rothermel**

**Wilmer Cutler Pickering Hale and Dorr LLP**

Edgar Filing: Verastem, Inc. - Form SC 13D/A

60 State Street

Boston, Massachusetts 02109

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

November 1, 2012

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

**Note.** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

---

CUSIP No. 92337C104

13D

- (1) Names of Reporting Persons  
Longwood Fund, L.P.
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a)   
 (b)
- (3) SEC Use Only
- (4) Source of Funds (See Instructions)  
WC
- (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e).
- (6) Citizenship or Place of Organization.  
Delaware, United States of America
- (7) Sole Voting Power.  
0
- Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With:
- (8) Shared Voting Power.  
2,869,841
- (9) Sole Dispositive Power.  
0
- (10) Shared Dispositive Power.  
2,869,841
- (11) Aggregate Amount Beneficially Owned by Each Reporting Person.  
2,869,841 (see Attachment A)
- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions).
- (13) Percent of Class Represented by Amount in Row (11).  
13.5% (see Attachment A)
- (14) Type of Reporting Person (See Instructions).  
PN

CUSIP No. 92337C104

13D

- (1) Names of Reporting Persons  
Longwood Fund GP, LLC
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a)   
 (b)
- (3) SEC Use Only
- (4) Source of Funds (See Instructions)  
WC
- (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e).
- (6) Citizenship or Place of Organization.  
Delaware, United States of America
- (7) Sole Voting Power.  
0
- Number of Shares Beneficially Owned by Each Reporting Person With:
- (8) Shared Voting Power.  
2,869,841
- (9) Sole Dispositive Power.  
0
- (10) Shared Dispositive Power.  
2,869,841
- (11) Aggregate Amount Beneficially Owned by Each Reporting Person.  
2,869,841 (see Attachment A)
- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions).
- (13) Percent of Class Represented by Amount in Row (11).  
13.5% (see Attachment A)
- (14) Type of Reporting Person (See Instructions).  
OO

CUSIP No. 92337C104

13D

- (1) Names of Reporting Persons  
Christoph Westphal, M.D., Ph.D.
- (2) Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)   
(b)
- (3) SEC Use Only
- (4) Source of Funds (See Instructions)  
AF
- (5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e).
- (6) Citizenship or Place of Organization.  
United States citizen
- |  |      |  |
|--|------|--|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With: | (7)  | Sole Voting Power.<br>776,886          |
|  | (8)  | Shared Voting Power.<br>2,995,555      |
|  | (9)  | Sole Dispositive Power.<br>776,886     |
|  | (10) | Shared Dispositive Power.<br>2,995,555 |
- (11) Aggregate Amount Beneficially Owned by Each Reporting Person.  
3,772,441 (see Attachment A)
- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions).
- (13) Percent of Class Represented by Amount in Row (11).  
17.7% (see Attachment A)
- (14) Type of Reporting Person (See Instructions).  
IN

CUSIP No. 92337C104

13D

- (15) Names of Reporting Persons  
Richard Aldrich
- (16) Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)   
(b)
- (17) SEC Use Only
- (18) Source of Funds (See Instructions)  
AF
- (19) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e).
- (20) Citizenship or Place of Organization.  
United States citizen
- |  |      |  |
|--|------|--|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With: | (21) | Sole Voting Power.<br>419,642          |
|  | (22) | Shared Voting Power.<br>3,005,555      |
|  | (23) | Sole Dispositive Power.<br>419,642     |
|  | (24) | Shared Dispositive Power.<br>3,005,555 |
- (25) Aggregate Amount Beneficially Owned by Each Reporting Person.  
3,425,197 (see Attachment A)
- (26) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions).
- (27) Percent of Class Represented by Amount in Row (11).  
16.1% (see Attachment A)
- (28) Type of Reporting Person (See Instructions).  
IN

CUSIP No. 92337C104

13D

- (29) Names of Reporting Persons  
Michelle Dipp, M.D., Ph.D.
- (30) Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)  o  
(b)  x
- (31) SEC Use Only
- (32) Source of Funds (See Instructions)  
AF
- (33) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e).  o
- (34) Citizenship or Place of Organization.  
United States citizen
- |  |      |  |
|--|------|--|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With: | (35) | Sole Voting Power.<br>171,428          |
|  | (36) | Shared Voting Power.<br>2,869,841      |
|  | (37) | Sole Dispositive Power.<br>171,428     |
|  | (38) | Shared Dispositive Power.<br>2,869,841 |
- (39) Aggregate Amount Beneficially Owned by Each Reporting Person.  
2,869,841 (see Attachment A)
- (40) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions).  o
- (41) Percent of Class Represented by Amount in Row (11).  
14.3% (see Attachment A)
- (42) Type of Reporting Person (See Instructions).  
IN

CUSIP No. 92337C104	13D	
---------------------	-----	--

**Item 1. Security and Issuer.**

This statement on Schedule 13D relates to the Reporting Persons (as defined in Item 2 below) beneficial ownership interest in the common stock, par value \$0.0001 per share (the Common stock), of Verastem, Inc., a Delaware corporation (the Issuer). The address of the principal executive office of the Issuer is 215 First Street, Suite 440, Cambridge, Massachusetts 02142. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 2. Identity and Background.**

(a) This statement is filed by:

(i) Longwood Fund, L.P. (the Fund), with respect to the shares of Common Stock directly and beneficially owned by it;

(ii) Longwood Fund GP, LLC (the General Partner), with respect to the shares of Common Stock directly and beneficially owned by it;

(iii) Christoph Westphal, M.D., Ph.D. ( Westphal ), with respect to the shares of Common Stock directly and beneficially owned by him;

(iv) Richard Aldrich ( Aldrich ), with respect to the shares of Common Stock directly and beneficially owned by him; and

(v) Michelle Dipp, M.D., Ph.D. ( Dipp ), with respect to the shares of Common Stock directly and beneficially owned by her.

Each of the foregoing is referred to as a Reporting Person and collectively as the Reporting Persons.

(b) The business address of each of the Reporting Persons:

Longwood Fund  
Prudential Tower, Suite 1555



Edgar Filing: Verastem, Inc. - Form SC 13D/A

800 Boylston Street  
Boston, Massachusetts 02199

(c) The present principal business of each of the Reporting Persons is the venture capital investment business.

(d) No Reporting Person, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) No Reporting Person, during the last five years, has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Citizenship.

The Fund	Delaware, United States of America
The General Partner	Delaware, United States of America
Westphal	United States of America
Aldrich	United States of America
Dipp	United States of America

**Item 3. Source and Amount of Funds or Other Consideration.**

In August 2010, in connection with the Issuer's formation, the Issuer sold to Dr. Westphal 628,571 shares of Common Stock. Dr. Westphal subsequently transferred 125,714 of those shares to the Fountain Irrevocable Trust of 2010. Also in August 2010, in connection with the Issuer's formation, the Issuer sold to Mr. Aldrich 542,856 shares of Common Stock. Mr. Aldrich subsequently transferred 135,714 of those shares to the Richard H. Aldrich Irrevocable Trust of 2011. (These numbers give effect to the one-for-3.5 reverse stock split of the

CUSIP No. 92337C104	13D	
---------------------	-----	--

Issuer's Common Stock that was effective on January 10, 2012.) All such shares were purchased with the holder's personal funds.

From November 3, 2010 through November 1, 2011, the Reporting Persons acquired an aggregate of (i) 4,000,000 shares of Series A convertible preferred stock of the Issuer, (ii) 3,500,000 shares of Series B convertible preferred stock of the Issuer and (iii) 444,444 shares of Series C convertible preferred stock of the Issuer. The Issuer acquired such shares for an aggregate purchase price of approximately \$12 million. All such shares were acquired with working capital.

Following completion of the Issuer's initial public offering on February 1, 2012 (the IPO), the Reporting Persons' shares of the Issuer's Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock were converted into Common Stock on a 1-for-3.5 basis.

After the conversion of the Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock into Common Stock, the Reporting Persons owned 2,269,841 shares of Common Stock.

In conjunction with the Issuer's IPO, the Fund purchased 600,000 shares of Common Stock, resulting in an increase in beneficial ownership by the Reporting Persons by that amount. The purchase was made at the initial public offering price of \$10.00 per share, for an aggregate purchase price of \$6,000,000. The working capital of the Fund was the source of funds for the purchase of the shares of Common Stock.

In March 2012, the Issuer granted options to purchase 12,500 shares of Common Stock to each of Dr. Westphal and Mr. Aldrich. All such options will be fully vested within 60 days of the date hereof. Such options were granted at no cost to Dr. Westphal and Mr. Aldrich. On September 18, 2012, the Issuer granted options to purchase 625,000 shares of Common Stock to Dr. Westphal, 195,313 of which will be vested within 60 days of the date hereof. Also on September 18, 2012, the Issuer granted 206,612 restricted stock units to Dr. Westphal, 63,316 of which will be vested within 60 days of the date hereof. Such options and restricted stock units were granted at no cost to Dr. Westphal.

Between December 21, 2012 and January 29, 2013, Dr. Westphal purchased 2,900 shares of Common Stock pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2012 using his personal funds.

#### **Item 4. Purpose of Transaction.**

The shares of capital stock reported herein were acquired solely for investment purposes. None of the Reporting Persons have any present plans or proposals that relate to or would result in any change in the business, policies, management, structure or capitalization of the Issuer. The Reporting Persons reserve the right to acquire, or dispose of, additional securities of the Issuer in the ordinary course of their business, to the extent deemed advisable in light of their general investment and trading policies, market conditions or other factors. The Reporting Persons may engage in discussions from time to time with other stockholders of the Issuer regarding the acquisition by the Reporting Persons of others of shares of the Issuer's Common Stock held by such stockholders.

## Edgar Filing: Verastem, Inc. - Form SC 13D/A

Dr. Westphal adopted a Rule 10b5-1 trading plan on November 20, 2012, and from time to time may acquire additional securities of the Issuer under such plan.

Dr. Westphal is the CEO of the Issuer and is also a manager of the General Partner. Mr. Aldrich is a member of the Board of Directors of the Issuers and is also a manager of the General Partner.

The Reporting Persons may seek information from management and the Issuer's Board of Directors, and may engage in further discussions with management, the Issuer's Board of Directors, other stockholders of the Issuer and other relevant parties, concerning the business, operations, governance, management, strategy, capitalization and/or future plans of the Issuer, or in proposing one or more of the other actions described in subparagraphs (a) through (j) of this Item 4. In addition, the Reporting Persons may exercise their rights under the Investors' Rights Agreement, as defined below.

Other than as described above and as set forth in the Investors' Rights Agreement, as defined below, the Reporting Persons do not have any plans or proposals which would result in any of the following:

CUSIP No. 92337C104	13D	
---------------------	-----	--

- (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;
- (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;
- (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;
- (d) Any change in the present Issuer's board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
- (e) Any material change in the present capitalization or dividend policy of the Issuer;
- (f) Any other material change in the Issuer's business or corporate structure;
- (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions that may impede the acquisition of control of the Issuer by any person;
- (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
- (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or
- (j) Any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer.**

## Edgar Filing: Verastem, Inc. - Form SC 13D/A

The aggregate percentage of shares of Common Stock reported beneficially owned by each person named herein is determined in accordance with SEC rules and is based upon 21,255,058 shares of the Issuer's Common Stock outstanding as of November 5, 2012, as reported on the Issuer's most recent Quarterly Report on Form 10-Q. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities.

### **A. Longwood Fund, L.P.**

(a) As of the closing of business on January 31, 2013, the Fund beneficially owned 2,869,841 shares of Common Stock, representing a beneficial ownership of approximately 13.5% of the shares of Common Stock. All such shares are directly held by the Fund.

(b)	1. Sole power to vote or direct vote:	0
	2. Shared power to vote or direct vote:	2,869,841
	3. Sole power to dispose or direct the disposition:	0
	4. Shared power to dispose or direct the disposition:	2,869,841

Please see Attachment A for additional information.

### **B. Longwood Fund GP, LLC**

(a) As of the closing of business on January 31, 2013, the General Partner beneficially owned 2,869,841 shares of Common Stock, representing a beneficial ownership of approximately 13.5% of the shares of Common Stock. All such shares are directly held by the Fund.

(b)	1. Sole power to vote or direct vote:	0
	2. Shared power to vote or direct vote:	2,869,841
	3. Sole power to dispose or direct the disposition:	0
	4. Shared power to dispose or direct the disposition:	2,869,841

Please see Attachment A for additional information.

CUSIP No. 92337C104

13D

**C. Christoph Westphal, M.D., Ph.D.**

(a) As of the closing of business on January 31, 2013, Christoph Westphal, M.D., Ph.D. beneficially owned 3,772,441 shares of Common Stock, representing a beneficial ownership of approximately 17.7% of the shares of Common Stock. 505,757 such shares are held by Dr. Westphal directly, 125,714 shares are held by the Fountain Irrevocable Trust of 2010, 2,869,841 shares are held by the Fund, 207,813 shares represent options that are exercisable within 60 days of the date hereof and 63,316 shares represent restricted stock units that vest within 60 days of the date hereof.

(b)	1. Sole power to vote or direct vote:	776,886
	2. Shared power to vote or direct vote:	2,995,555
	3. Sole power to dispose or direct the disposition:	776,886
	4. Shared power to dispose or direct the disposition:	2,995,555

Please see Attachment A for additional information.

**D. Richard Aldrich**

(a) As of the closing of business on January 31, 2013, Richard Aldrich beneficially owned 3,425,197 shares of Common Stock, representing a beneficial ownership of approximately 16.1% of the shares of Common Stock. 407,142 shares are held by Mr. Aldrich directly, 135,714 shares are held by the Richard H. Aldrich Irrevocable Trust of 2011, 2,869,841 shares are held by the Fund, and 12,500 shares represent options that are exercisable within 60 days of the date hereof.

(b)	1. Sole power to vote or direct vote:	419,642
	2. Shared power to vote or direct vote:	3,005,555
	3. Sole power to dispose or direct the disposition:	419,642
	4. Shared power to dispose or direct the disposition:	3,005,555

Please see Attachment A for additional information.

**E. Michelle Dipp, M.D., Ph.D.**

2,869,841

Edgar Filing: Verastem, Inc. - Form SC 13D/A

(a) As of the closing of business on January 31, 2013, Michelle Dipp, M.D., Ph.D. beneficially owned 3,041,269 shares of Common Stock, representing a beneficial ownership of approximately 14.3% of the shares of Common Stock. All such shares are directly held by the Fund.

(b)	1. Sole power to vote or direct vote:	171,428
	2. Shared power to vote or direct vote:	2,869,841
	3. Sole power to dispose or direct the disposition:	171,428
	4. Shared power to dispose or direct the disposition:	2,869,841

Please see Attachment A for additional information.

(c) On December 21, Dr. Westphal purchased 100 shares of Common Stock for \$8.72 per share, 124 shares of Common Stock for \$8.77 per share, 100 shares of Common Stock for \$8.79 per share, 200 shares of Common Stock for \$8.87 per share, and 476 shares of Common Stock for \$8.91 per share. On January 2, 2013, Dr. Westphal purchased 800 shares of Common Stock for \$9.73 per share. On January 18, 2013, Dr. Westphal purchased 100 shares of Common Stock for \$9.97 per share, 198 shares of Common Stock for \$9.99 per share, and 502 shares of Common Stock for \$10.00 per share. On January 29, 2013, Dr. Westphal purchased 300 shares of Common Stock for \$10 per share. Such purchases were made pursuant to a Rule 10b5-1 trading plan adopted by Dr. Westphal on November 20, 2012.

(d) Not applicable.

CUSIP No. 92337C104

13D

(e) Not applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.****Second Amended and Restated Investors Rights Agreement**

The Reporting Persons and certain other stockholders (collectively, the *Holder*s ) of the Issuer have entered into a Second Amended and Restated Investors Rights Agreement dated November 1, 2011 (the *Investors Rights Agreement* ) with the Issuer. Subject to the terms of the Investors Rights Agreement, holders of shares having registration rights ( *Registrable Securities* ) can demand that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing.

*Demand Registration Rights*

If, at any time after June 24, 2012, the Issuer shall receive a written request from the *Holder*s (as defined in the *Investors Rights Agreement*) of at least a majority of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed \$5,000,000) (the *Initiating Holder*s ) that the Issuer file a Form S-1 registration statement under the Securities Act of 1933 (the *Securities Act* ), then the Issuer shall (i) within ten (10) days after the date such request is given, give notice thereof (the *Demand Notice* ) to all *Holder*s other than the *Initiating Holder*s; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the *Initiating Holder*s, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the *Initiating Holder*s requested to be registered and any additional Registrable Securities requested to be included in such registration by any other *Holder*s.

The Issuer shall not be obligated to effect, or to take any action to effect, any demand registration if the Issuer has effected two Form S-1 demand registrations.

*Piggyback Registration Rights*

If the Issuer proposes to register any of its stock in connection with the public offering of such securities by the Issuer or on behalf of selling stockholders, the Issuer shall, at such time, promptly give each *Holder* written notice of such registration. Upon the written request of each *Holder*, the Issuer shall, subject to the certain limitations, use its reasonable best efforts to cause to be registered all of the Registrable Securities that each such *Holder* has requested to be registered.

*Form S-3 Demand Registration Rights*



If at any time when it is eligible to use a Form S-3 registration statement, the Issuer receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Issuer file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least \$1,000,000, then the Issuer shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders.

The Issuer shall not be obligated to effect, or to take any action to effect, any Form S-3 demand registration if the Issuer has effected two Form S-3 demand registrations within the twelve month period immediately preceding the date of such request.

*Registration Expenses*

Subject to certain limitations, the Issuer will pay all expenses incurred in connection with the exercise of demand and piggyback registration rights, except for underwriting discounts and commissions.

CUSIP No. 92337C104

13D

*Indemnification*

The Investor Rights Agreement contains customary cross-indemnification provisions, pursuant to which the Issuer is obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to the Issuer, and the selling stockholders are obligated to indemnify the Issuer for material misstatements or omissions attributable to them.

*Expiration of Registration Rights*

No Holder shall be entitled to exercise any registration rights after the earlier of: (i) the closing of a Deemed Liquidation Event (as such term is defined in the Issuer's Certificate of Incorporation); and (ii) the fifth anniversary of the Issuer's after the completion of the Issuer's IPO.

Holders of all of the Issuer's shares with these registration rights signed agreements with the underwriters prohibiting the exercise of their registration rights for 180 days or 360 days, as applicable, subject to a possible extension beyond the end of such 180-day or 360-day period, as applicable, following the date of the completion of the Issuer's IPO.

**Lock-up Agreements**

The Fund, Westphal and Aldrich, along with the Issuer's officers and directors and holders of all of its outstanding securities have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of the Issuer's Common Stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the Issuer's Common Stock, whether any of these transactions are to be settled by delivery of the Issuer's Common Stock or other securities, in cash or otherwise, or publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of the representatives of the underwriters for a period of 180 days or 360 days, as applicable, after February 1, 2012, except for transfers of shares of its Common Stock to a family member or trust, provided the transferee agrees to be bound in writing by the terms of the lock-up prior to such transfer, such transfer does not involve a disposition for value and no filing by any party (donor, donee, transferor or transferee) under the Exchange Act be required or be voluntarily made in connection with such transfer (other than a filing on a Form 5 made after the expiration of the lock-up period).

The 180-day or 360-day restricted period under the agreements with the underwriters described above will be automatically extended if: (1) during the period that begins on the date that is 15 calendar days plus 3 business days before the last day of the 180-day or 360-day restricted period and ends on the last day of the 180-day or 360-day restricted period, the Issuer issues an earnings release or material news or a material event relating to the Issuer occurs; or (2) prior to the expiration of the 180-day or 360-day restricted period, the Issuer announces that it will release earnings results or becomes aware that material news or a material event relating to the Issuer will occur during the 16-day period beginning on the last day of the 180-day or 360-day restricted period, in which case the restrictions described in the preceding paragraph will continue to apply until the date that is 15 calendar days plus 3 business days after the date of the issuance of the earnings release or the occurrence of the material news or material event.

## Edgar Filing: Verastem, Inc. - Form SC 13D/A

The foregoing description of the terms of the Investor Rights Agreement and the Lock-up Agreement is intended as a summary only and is qualified in its entirety by reference to the Investor Rights Agreement and Form of Lock-up Agreement, which are filed as exhibits to this Schedule 13D and incorporated by reference herein.

Other than as described in this Schedule 13D, to the best of the Reporting Persons' knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.

CUSIP No. 92337C104	13D	
---------------------	-----	--

**Item 7. Material to be Filed as Exhibits.**

The following documents are filed as Exhibits to this statement:

**Exhibit**

<b>Number</b>	<b>Exhibit Description</b>
99.1	Joint Filing Agreement
99.2	Second Amended and Restated Investors Rights Agreement dated as of November 1, 2011, among the Issuer and the Issuer's securityholders listed therein (Incorporated by reference to Exhibit 4.2 of the Issuer's Registration Statement of Form S-1 (SEC File No. 333-177677), filed with the Securities and Exchange Commission (the <u>SEC</u> ) on November 3, 2011).
99.3	Form of Lock-up Agreement (Incorporated by reference to Exhibit 99.3 of the Schedule 13D filed with the SEC by the Reporting Persons on February 14, 2012)

CUSIP No. 92337C104	13D	
---------------------	-----	--

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

Dated: February 8, 2013

**LONGWOOD FUND, L.P.**

By: Longwood Fund GP, LLC, a  
Delaware limited liability company and  
general partner of Longwood Fund, L.P.

By: /s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D., Manager

**LONGWOOD FUND GP, LLC**

By: /s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D., Manager

/s/ Christoph Westphal  
Christoph Westphal, M.D., Ph.D.

/s/ Richard Aldrich  
Richard Aldrich

/s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D.

CUSIP No. 92337C104	13D	
---------------------	-----	--

**ATTACHMENT A**

Each Reporting Person disclaims beneficial ownership of the shares described above except to the extent of his or its pecuniary interest therein.

CUSIP No. 92337C104	13D	
---------------------	-----	--

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D/A to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.

**LONGWOOD FUND, L.P.**

By: Longwood Fund GP, LLC, a  
Delaware limited liability company and  
general partner of Longwood Fund, L.P.

By: /s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D., Manager

**LONGWOOD FUND GP, LLC**

By: /s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D., Manager

/s/ Christoph Westphal  
Christoph Westphal, M.D., Ph.D.

/s/ Richard Aldrich  
Richard Aldrich

/s/ Michelle Dipp  
Michelle Dipp, M.D., Ph.D.